rVSVN4CT1-EBOVGP1 Ebola virus vaccine demonstrates safety and immunogenicity in phase I study Jan. 22, 2020
ASIT Biotech publishes phase III data for gp-ASIT+ grass allergen peptide immunotherapy Jan. 20, 2020
RSS